_	

2 Cytosolic PCNA interacts with S100A8 and controls an inflammatory subset of neutrophils in COVID-19

3

Rodrigo de Oliveira Formiga^{1,2}, Lucie Pesenti¹, Maha Zohra Ladjemi¹, Philippe Frachet³, Muriel Andrieu¹,
Souganya Many¹, Vaarany Karunanithy¹, Karine Bailly¹, Théo Dhôte¹, Manon Castel¹, Christophe
Rousseau¹, Marick Starick², Edroaldo Lummertz da Rocha², Emilia Puig Lombardi⁴, Vanessa Granger^{5,6},
Sylvie Chollet-Martin^{5,6}, Luc De Chaisemartin^{5,6}, Luc Mouthon^{1,7}, Fernando Spiller², Anne Hosmalin¹,
Margarita Hurtado-Nedelec⁸, Clémence Martin^{1,9}, Frédéric Pène^{1,10}, Pierre-Regis Burgel^{1,9}, Léa Tourneur¹,
Véronique Witko-Sarsat^{1,*}

10

11 ¹Université Paris Cité, INSERM U1016, CNRS 8104, Institut Cochin, Paris, France; ²Laboratory of 12 Immunobiology, Department of Pharmacology, Federal University of Santa Catarina (UFSC), Florianopolis, 13 Santa Catarina, Brazil; ³Université Grenoble Alpes, CEA, CNRS, IBS, Grenoble, France; ⁴Bioinformatics Core 14 Platform, INSERM UMR1163, Imagine Institute, Université Paris Cité, Paris, France; ⁵APHP, Immunology 15 department, Auto-immunity, hypersensitivities and biologicals, Bichat Hospital, Paris, France; ⁶Paris-Saclay University, INSERM, Inflammation, microbiome and immunosurveillance, Châtenay-Malabry, 16 17 France; ⁷ Department of Internal Medicine, AP-HP, Cochin Hospital, Paris, France; ⁸Department of 18 Immunology and Hematology, UF Immune Dysfunctions, HUPNVS, Bichat Hospital, Paris, France; ⁹Department of Pneumology, AP-HP, Cochin Hospital, Paris, France; ¹⁰Department of Intensive Medicine 19 20 and Reanimation, AP-HP, Cochin Hospital, Paris, France.

21

22 Correspondence: Véronique Witko-Sarsat, Institut Cochin - Bâtiment Roussy, 27 Rue du Faubourg Saint-

23 Jacques - 75014 PARIS ; e-mail: veronique.witko@inserm.fr

24

25 Running title: PCNA-S100A8 interaction in neutrophils in COVID-19

26

27 Key words: Neutrophils; PCNA; S100A8, COVID-19

28

29

31 Abstract

32

33 Neutrophils are key players in the hyperinflammatory response upon SARS-CoV-2 infection. We have 34 previously described that cytosolic proliferating cell nuclear antigen (PCNA) controls neutrophil survival 35 and NADPH oxidase-dependent ROS production. We here show that both PCNA and S100A8 expression and interaction were elevated in neutrophils from patients with COVID-19 compared to healthy donors 36 37 and this was correlated with disease severity. Increased PCNA expression was accompanied by a decreased apoptosis and increased NADPH-oxidase activity in neutrophils from COVID-19 patients 38 39 compared to healthy donors. These effects, as well as the interaction between PCNA and S100A8, were 40 potently counteracted by T2 amino alcohol (T2AA), a PCNA inhibitor, demonstrating that the PCNA scaffold orchestrated neutrophil activation. Notably, the interaction between PCNA-S100A8 was more 41 intense in the CD16^{high}-CD62L^{low} activated neutrophil subset. We propose that PCNA-S100A8 complex acts 42 43 as potential driver for neutrophil dysregulation in COVID-19 and show for the first time that the PCNA 44 scaffold is a decisive component of both neutrophil activation and heterogeneity.

46 Introduction

Neutrophils are key players in the innate immune response and form the first line of defense against 47 48 infectious agents, as they employ well-characterized anti-microbial strategies, such as phagocytosis or release of reactive oxygen species (ROS)¹, neutrophil extracellular traps (NETs)² and other pro-49 inflammatory mediators.^{3,4} Recent unexpected biological features, such as their phenotypic and functional 50 51 heterogeneity,⁵ their extended lifespan under certain pathological conditions have highlighted their crucial role in controlling adaptive immune responses.^{6–8} Increased neutrophil counts and newly 52 identified subsets with characteristics of immaturity, immunosuppression, activation, and metabolic 53 rewiring in both circulation and infiltrated into the respiratory tract may be pivotal clinical aspects of 54 severe Coronavirus Disease (COVID)-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-55 CoV-2).⁸ Upon SARS-CoV-2 infection, a wide spectrum of clinical outcomes may appear, ranging from self-56 57 limited asymptomatic⁹ or mild disease to severe cases, the last marked by thromboembolic events,¹⁰ dysregulated immune response,¹¹ and respiratory distress and multiorgan failure.^{8,12–15} 58

In COVID-19 the circulating levels of calprotectin, also known as S100A8/A9, are highly abundant and are associated with immune imbalance and expansion of aberrant neutrophil subpopulations that correlated with disease severity.¹⁶⁻¹⁷ Indeed, calprotectin is a potential biomarker in a wide number of inflammatory conditions in which neutrophils are involved, such as autoimmune vasculitis,¹⁸ arthritis,¹⁹ cardiovascular, and metabolic disorders. The S100A8/A9 is constitutively expressed in neutrophils and monocytes, a Ca2+ sensor, participates in cytoskeleton rearrangement and arachidonic acid metabolism.²⁰ Neutrophil secretion of S100A8/A9 might act as a extracellular signaling mediator.²¹

To gain insights into the molecular mechanisms involved in neutrophil dysregulation and reprogramming 66 observed in COVID-19 patients, we examined the expression and function of the proliferating cell nuclear 67 antigen (PCNA), which we previously described as a key regulator of neutrophil fate.^{22,23} PCNA is a 68 scaffolding protein expressed in the nucleus of proliferating cells where it controls DNA replication and 69 70 repair.^{24,25} By contrast, in neutrophils, which are non-proliferative cells, PCNA is exclusively cytoplasmic²⁶ 71 and interacts with procaspases to promote neutrophil survival.^{22,27} Notably, T2 amino alcohol (T2AA)^{28,29}, a small molecule inhibitor that specifically binds to PCNA promotes the resolution of inflammation in a 72 73 model of murine colitis. Proteomic analysis of neutrophil PCNA interactome identified a diversity of proteins involved in different functions, including cytoskeletal regulation, metabolism,³⁰ and NADPH 74 75 oxidase. Indeed, PCNA interacts directly with p47^{phox}, a NADPH oxidase subunit, to control the oxidative burst.³¹ Likewise, calprotectin promotes NADPH oxidase complex assembly and ROS generation through 76

direct interactions between S100A8 and the cytosolic subunit p67^{phox32} and between S100A9 and the

78 cytochrome b558 protein, gp91^{phox.33}

79 The aim of this study is to examine whether and how the cytosolic proteins PCNA and S100A8/A9 may be

80 involved in the dysregulated function of neutrophils in COVID-19 patients of various severity. We herein

81 identify a pivotal role of cytosolic PCNA in promoting survival and NADPH oxidase-dependent ROS

production in neutrophils, notably through its enhanced interaction with the S100A8 protein. Most

83 strikingly, this PCNA-S100A8 interaction in neutrophil cytosol was found in a particular neutrophil subset

84 and was related to COVID-19 severity.

86 Results

Increased PCNA expression is associated with increased survival in neutrophils from COVID-19 patients 87 88 Western blot analysis of PCNA in neutrophils from HD and COVID-19 patients showed an increase in PCNA 89 cytosolic expression correlating with disease severity with significant differences between critical patients 90 and HD, as well as severe patients and HD. However, no significant changes were found between 91 HD/moderate or severe/critical patients (Figures 1A-B). Increased PCNA expression in neutrophils from 92 both severe and critical COVID-19 patients was confirmed by immunofluorescence labelling of PCNA that displayed a cytoplasmic pattern (Figures 1C-D). Re-analysis of publicly available scRNA-seq data^{16,41} 93 94 pointed to no changes in PCNA mRNA in circulating or respiratory tract infiltrating neutrophils in severe 95 COVID-19 patients (Supplemental Figure 2). Notably, the PCNA cytosolic expression was correlated with circulating NETs (Figures 1E-F), neutrophil elastase (Figures 1G-H) and calprotectin levels (Figures 1I-J) 96 97 strongly suggesting that cytosolic PCNA was pivotal in neutrophil activation state and was reminiscent of 98 systemic inflammation. 99 We next evaluated the ability of neutrophils from COVID-19 patients to undergo spontaneous apoptosis

100 after a 16h in vitro incubation by measuring annexin-V binding on externalized phosphatidylserine. As 101 expected, neutrophils from severe and critical COVID-19 patients were significantly more viable, less 102 apoptotic, and less necrotic (evaluated by 7AAD labelling) than HD neutrophils (Figure 2A-C). Notably, T2AA, a PCNA inhibitor,^{28,29} significantly decreased the survival of COVID-19 neutrophils by increasing 103 104 apoptosis (Figure 2A-C). This increased survival was confirmed by a significantly stronger DiOC6 labelling 105 thereby indicating a preserved mitochondrial membrane potential ($\Delta \psi m$) during overnight incubation as 106 compared to HD. This sustained $\Delta \psi m$ was reversed by disrupting the PCNA scaffold by T2AA (Figure 2D), 107 again highlighting the key role of PCNA in survival of COVID-19 neutrophils.

In accordance with the notion that cytosolic PCNA inhibits apoptosis,²² Western blot analysis confirmed that PCNA expression was significantly decreased after apoptosis in HD neutrophils. By contrast, COVID-19 neutrophils maintained high amounts of PCNA even after spontaneous apoptosis and this was particularly pronounced in critically ill patients who display the highest level of PCNA (Figure 2E).

112

Cytosolic PCNA controls sustained NADPH oxidase-dependent ROS production in neutrophils from COVID-19 patients

115 We next examined NADPH oxidase-dependent ROS production to evaluate the activation state of COVID-

116 19 neutrophils. No significant difference in ROS production was found between neutrophils from COVID-

117 19 patients with a moderate severity compared to HD at basal state or after *in vitro* activation by PMA,

opsonized zymosan or f-MLF. By contrast, neutrophils from severe and critical COVID-19 patients had a 118 significant increase in basal ROS production compared to HD showing that they were activated in the 119 120 absence of *in vitro* stimulus (Figure 3A). ROS production was significantly increased after PMA, opsonized 121 zymosan, or f-MLF stimulation in severe COVID-19 patients as compared with HD, suggesting that this 122 increased ROS production was associated with the severity of the disease to some extent. Notably, 123 inhibition of the PCNA scaffold by T2AA resulted in a significant decrease in either basal (Figure 3A) or 124 stimulated ROS production (Figure 3B-D) in COVID-19 neutrophils whatever the severity of the disease. 125 Accordingly, T2AA decreased NADPH-oxidase dependent ROS production at higher concentrations in COVID-19 compared to HD neutrophils (Supplemental Figure 3). Taken together, our data suggest that 126 127 PCNA sustains NADPH oxidase-dependent ROS production in COVID-19 neutrophils.

We previously showed that PCNA can directly bind to the cytosolic p47^{phox} protein, acting as a chaperone to promote NADPH oxidase activation.³¹ We here confirmed that the PCNA-p47^{phox} association evaluated by a proximity ligation assay was detected in HD neutrophils at basal state but was absent after PMA activation as previously reported.³⁷ By contrast, the PCNA-p47^{phox} association was undetectable in neutrophils from severe COVID-19 patients (Figure 2E-F) strongly supporting the notion that they were activated at the basal state.

134

135

S100A8 is a new partner of PCNA which is overexpressed in neutrophils cytosols from COVID-19 patients 136 137 S100A8 or S100A9 have been described to promote NADPH oxidase activity through their association with 138 cytosolic NADPH oxidase components.^{32,33} Since calprotectin serum levels are positively correlated with neutrophil activation and COVID-19 severity,^{16,42} we next tested whether S100A8 or S100A9 could be part 139 140 of the PCNA scaffold thereby supporting neutrophil dysregulation in COVID-19. Surface plasmon 141 resonance (SPR) was carried out to examine whether PCNA could directly interact with either S100A8 or 142 S100A9 or with the dimeric S100A8/A9 calprotectin. Our data unambiguously showed that there was a 143 direct S100A8 association with immobilized PCNA in a concentration-dependent manner ($0.1-2\mu M$) with 144 an equilibrium dissociation constant (K_D) value within the micromolar range (Figure 4A; Table 2). By 145 contrast, S100A9 and the S100A8/A9 heterodimer failed to associate with PCNA when assayed under the same experimental settings (Figure 4B; Table 2). We confirmed, using a proximity ligation assay, that PCNA 146 147 and S100A8 were associated within the cytoplasm under basal conditions in neutrophils from both HD and COVID-19 patients but the PCNA-S100A8 proximity-induced fluorescence intensity was significantly 148 149 increased in the latter. Notably, T2AA treatment, by interfering with the PCNA scaffold, significantly

150 blunted the PCNA-S100A8 interaction (Figure 4C-D). Pertinently, using Western blot analysis, we observed an increased S100A8 cytosolic levels in COVID-19 neutrophils according to disease severity (Figure 4 E-F), 151 152 showing positive correlation with PCNA expression (Figure 4G). S100A8 immunofluorescence in 153 neutrophils from HD and severe COVID patients confirmed its cytoplasmic localization (Figure 4H). 154 Increased fluorescence intensity consistent with increased S100A8 expression was observed in COVID-19 155 neutrophils compared to those of HD (Figure 4I). Notably, analysis of publicly available scRNA-seg data^{16,41} 156 showed that S100A8 and S100A9 mRNA percentage and average of expression were altered in COVID-19 157 peripheral neutrophils, and high S100A8 mRNA levels were detected in respiratory tract infiltrating 158 neutrophils, showing higher expression levels in critical over moderate patients (Supplemental Figures 2). 159

Neutrophils from COVID-19 patients present altered phenotype related with activation and immaturity 160 161 Neutrophils from both severe and critical COVID-19 patients showed increased levels of adhesion molecules such as integrin CD11b, CD66b (CEACAM8), the receptor-linked protein tyrosine phosphatase 162 163 CD45, the metabolic marker lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and 164 programmed cell death protein ligand 1 (PDL-1), as well as decreased levels of CD62L (L-selectin) strongly 165 suggesting that neutrophil from severe and critical COVID-19 patients were activated (Figure 5A). 166 Moreover, a decreased expression of neutral endopeptidase CD10 was observed in COVID-19 patients 167 compared to HD. Frequency of neutrophils expressing CD10 was decreased while frequency of those expressing LOX-1, PDL-1, Siglec-3 CD33 and CD114 was increased compared to HD (Supplemental Figure 168 169 4). Non-supervised analysis of neutrophils from HD, severe and critical COVID-19 patients showed an 170 overall decrease in CD62L and increase in CD11b expression in the critical COVID-19 group (Figure 5B). We 171 identified an enrichment of a neutrophil subset in critical COVID-19 patients, composed of very mature neutrophils (CD10^{high}), with a particularly high activation state (CD11b^{high}, CD66b^{high} and a LOX-1^{high} and 172 173 CD114^{high} expression. The expansion of this hyperactivated subset of neutrophils is consistent with the 174 overwhelming inflammatory state of critical COVID-19 patients.

175

PCNA-S100A8 cytosolic interaction is increased in an hyperactivated subset of CD16^{high}/CD62L^{low} neutrophils in COVID-19

Owing to this neutrophil heterogeneity in COVID-19 patients, we next reasoned that the PCNA-S100A8
 interaction may be associated with a particular subset of neutrophils endowed with specific functions. To
 address this issue, we evaluated the phenotype of neutrophils using a previously described gate strategy⁴³

according to the CD16/CD62L staining pattern. In HD, most neutrophils presented high levels of CD16 and
 CD62L (CD16^{high}/CD62L^{high}), representing the conventional phenotype while the other subsets
 (CD16^{high}/CD62L^{low}, CD16^{low}/CD62L^{low} and CD16^{low}/CD62L^{high}) were approximately 1%. In severe and critical
 COVID-19, we observed an expansion of neutrophil subsets presenting CD16^{high}/CD62L^{low} (2),
 CD16^{low}/CD62L^{low} (3) and CD16^{low}/CD62L^{high} (4) characteristics and a decrease in the conventional
 CD16^{high}/CD62L^{high} neutrophils was found (Figure 6A-B).

187 Next, a Duolink proximity ligation assay was performed in combination with CD16/CD62L surface marker 188 immunolabelling and was analyzed by flow cytometry. In HD, we noticed that the PCNA-S100A8 interaction was more intense in the conventional CD16^{high}/CD62L^{high} subset (1) compared to the other 189 190 subsets. By contrast, in severe and critical COVID-19, the PCNA-S100A8 interaction was more intense in 191 the highly activated cells (CD16^{high}/CD62L^{low}) (2) than in the conventional CD16^{high}/CD62L^{high} subset, 192 strongly suggesting that the mechanisms leading to PCNA-S100A8 interaction could be different between 193 HD and COVID-19 patients (Figure 6C). This was further corroborated by the measurement of ROS 194 production after DCFCH staining combined with surface marker labelling analyzed by flow cytometry. 195 Remarkably, at the basal state, every neutrophil subset from COVID-19 patients produced more ROS than 196 their counterparts in HD (Figure 6D). This was also observed after PMA or opsonized zymosan stimulation 197 (Supplemental Figure 5) thereby confirming the sustained NADPH-oxidase-dependent ROS production. 198 Nonetheless, the ability of each subset to produce ROS in relation with the PCNA-S100A8 interaction seems to be different between HD and COVID-19 patients. In HD neutrophils, despite a lower level of 199 200 PCNA-S100A8 interaction the CD16^{high}/CD62L^{low} (2) subset (which represents less than 2% of the neutrophils) ROS production is higher in this subset compared to the conventional CD16^{high}/CD62L^{high} (1) 201 202 subset. In contrast, in COVID-19 neutrophils, the highest ROS production is observed in the CD16^{high}/CD62L^{low} (2) subset which also has the highest level of PCNA-S100A8 interaction strongly 203 204 suggesting that the PCNA-S100A8 interaction differentially affects ROS production in HD versus COVID-19 neutrophils. Furthermore, in COVID-19, the CD16^{high}/CD62L^{low} subset (2) had the largest expression of 205 CD11b (Figure 6E) and LOX-1 (Figure 6F), while showing decreased levels of CD10 when compared to 206 CD16^{high}/CD62L^{high} neutrophils (Figure 6G). In conclusion, the PCNA-S100A8 interaction is related to the 207 production of large amounts of ROS and took place in a specific subset of mature and hyperactivated 208 209 neutrophils from patients with severe COVID-19.

210

212 Discussion

An excessive inflammatory response and dysregulated neutrophil phenotype are hallmarks of COVID-19 213 infection^{15,21,44–51} but the molecular defects in the control of neutrophil functions are still unknown. PCNA 214 is a highly conserved scaffolding protein originally described in the nuclei of proliferating cells as a maestro 215 of the replication.^{24,25} Indeed, the latter process requires a myriad of proteins that should interact together 216 in a tightly regulated manner to maintain genome integrity.^{52,53} Likewise, neutrophil cytosolic PCNA 217 218 orchestrates a protein scaffold that controls neutrophil functions including apoptosis, NADPH oxidase activity, and metabolism.^{30,31} In addition, PCNA is a key regulator of neutrophil survival through 219 220 sequestration of procaspases to prevent their activation. During apoptosis, PCNA is degraded by the proteasome, thereby allowing the release of active caspases.²² In addition, the PCNA scaffold is extremely 221 versatile in response to neutrophil activation but until now all the functions of cytosolic PCNA are poorly 222 223 understood.

224 We first demonstrated that PCNA protein levels were increased in the cytosol of neutrophils according to COVID-19 severity. Of note, publicly available databases^{16,41} have not reported any increased PCNA mRNA 225 in neutrophils from COVID-19 patients, whereas a proteomic analysis performed on neutrophil lysates has 226 reported that PCNA was significantly upregulated in severe COVID-19 patients.¹⁵ This lack of 227 228 transcriptional regulation of PCNA in neutrophils is in keeping with our previous finding showing that 229 PCNA expression is significantly increased in neutrophils from donors treated with G-CSF or from patients 230 with chronic inflammatory disease without any mRNA modulation.²² Notably, in COVID-19 patients, 231 cytosolic PCNA levels were correlated with circulating markers of neutrophil-derived mediators such as 232 MPO-associated DNA (NETs), neutrophil elastase, or more importantly, with seric calprotectin 233 (S100A8/A9) concentration, this latter being a pronostic marker of the severity of the COVID-19.¹⁶ Indeed, 234 previous studies report its altered mRNA transcription in both circulating and respiratory tract infiltrated 235 neutrophils.^{16,41} We show for the first time that cytosolic S100A8 levels were significantly increased in 236 cytosols from COVID-19 neutrophils and that they correlated with those of PCNA. Moreover, PCNA 237 cytosolic levels were highly sustained even under physiological apoptosis conditions in neutrophils from severe/critical COVID-19 patients, thus maintaining their survival. S100A8, mainly localized in neutrophil 238 cytosols and released in culture supernatants in association with NETs⁵⁴, acts as a pro-survival factor 239 suppressing neutrophil apoptosis via a TLR4 and NF-KB dependent mechanism.^{55,56} Hence, we concluded 240 241 that both PCNA and S100A8 act together, favoring neutrophil survival and promoting their persistence in 242 inflammation sites during serious cases of COVID-19 thereby contributing to the worsening of critical 243 COVID-19 patients.

244 We previously demonstrated that PCNA is directly associated with the phox homology domain of the p47^{phox}, a key subunit of NADPH-oxidase to regulate ROS production in human neutrophils.³¹ At basal 245 246 state, this association prevents NADPH oxidase activation, whereas upon activation, PCNA acts as a chaperone by favoring its assembly and then dissociates from the p47^{phox} protein. Here, we showed that 247 the association between PCNA and p47^{phox} was disrupted in neutrophils from COVID-19 patients 248 249 suggesting a defect in this gate keeper function of PCNA on NADPH oxidase and presumably, a modified 250 PCNA scaffold. S100A8/S100A9 is also implicated in the positive modulation of the NADPH oxidase via molecular interactions with p67^{phox}, Rac-2,³² and cytochrome b₅₅₈,³³ respectively the cytosolic and 251 252 membrane associated components of the enzyme. We provide evidence that during COVID-19 PCNA was 253 preferentially associated with S100A8, a process dramatically inhibited by the PCNA scaffold inhibitor T2AA, thereby suggesting that the PCNA-S100A8 cytosolic partnership may potentiate NADPH-oxidase 254 255 activity, reinforcing the concept of PCNA as a key oxidative burst modulator in COVID-19. Unraveling the 256 molecular details of this PCNA-S100A8 interaction will require further structural biology experiments to determine the precise PCNA interacting domain in S100A8.^{57,58} Nonetheless, our findings may provide the 257 basis of a PCNA targeted therapy to specifically dampen this overactivation of NADPH oxidase. Using 258 phenotyping analysis combined with single cell analysis a robust enrichment of CD16^{low} neutrophil subsets 259 260 characterized by immaturity⁵⁹ and activation (CD62L^{low}) has been observed in severe COVID-19 patients.^{60–} 261 ⁶² Those cells are also characterized by higher levels of CD66b, LOX-1, and CD24, which are associated with early stages of neutrophil development in COVID-19.61,63 In another study, LOX-1-expressing immature 262 263 neutrophils are suggested to identify critically ill COVID-19 patients at risk of thrombotic complications.⁶⁴ 264 Regarding neutrophil phenotyping, we obtained similar results indicating that COVID-19 neutrophils are 265 basally activated with altered levels of CD11b, CD45, CD114 and CD62L, and characteristics of immaturity 266 and immunosuppression indicated by LOX-1, CD10 and CD16 assessment. Additionally, we found 267 neutrophils from COVID-19 express higher surface levels of PDL-1 and CD33 (Siglec-3), markers associated 268 with immunosuppression.^{21,61,65–67} Determination of the CD16/CD62L subsets in various conditions has 269 proven to be a reliable method to approach the phenotypic and functional analysis of neutrophil diversity^{43,59}. Neutrophils at homeostasis present very uniform expression of CD16 and CD62L 270 (CD16^{high}/CD62L^{high}) that progressively changes by the appearance of two other subpopulations after 271 intravenous LPS challenge, CD16^{low}/CD62L^{high} and CD16^{high}/CD62L^{low}.⁴³ According to a morphological and 272 273 functional analysis of those two subsets, CD16^{low}/CD62L^{high} have banded nuclei indicating immaturity and 274 show increased resistance to physiological apoptosis.⁴³ This subset is characteristic of acute inflammation observed in LPS exposure, bacterial sepsis, acute trauma⁶⁸. In contrast, CD16^{high}/CD62L^{low} neutrophils 275

276 present hyper segmented nuclei, high expression of activation markers, such as CD11b, CD11c and CD54 (ICAM), increased NADPH-oxidase activity, and T cell suppression effects.⁴³ Although this CD16^{high}/ 277 278 CD62L^{low} subset can be detected in some acute condition such as LPS injection, it seems to be a hallmark 279 of a chronic inflammatory challenge such as trauma or COVID-19. Notably, in the COVID-19 patients returning from ICU patients, the sorted CD16^{high}/ CD62L^{low} subset had a hypersegmented nuclear 280 281 morphology and show an increased CD11b expression suggesting an activated state. Accordingly, we also observed that in severe and critical COVID-19 neutrophils were CD16^{high}/CD62L^{high}, CD16^{high}/CD62L^{low} and 282 CD16^{low}/CD62L^{high}, but also as CD16^{low}/CD62L^{low}. This last population may represent an immature 283 neutrophil subset, marked by low levels of CD10. In addition, COVID-19 critical patients present higher 284 plasmatic levels of G-CSF, accompanied by an emergency myelopoiesis and early neutrophil release from 285 the bone marrow,^{67–70} explaining the expansion of CD16^{low} immature neutrophils.⁶⁹ In agreement, we 286 287 observed that severe and critical patients showed increased percentages of CD114⁺ neutrophils, the G-288 CSF receptor.

289 Most importantly, our study provides new insights about the impact of the PCNA scaffold on neutrophil 290 heterogeneity and functions, therefore proposing that PCNA may orchestrate dedicated functions in 291 specific subsets. Indeed, PCNA-S100A8 interaction was detected in conventional neutrophils, which display a very homogeneous CD16^{high}/CD62L^{high} phenotype. By contrast, in neutrophils from severe and 292 293 critical COVID-19 patients, we observed a dramatic increase in the intensity of this interaction but also a 294 radical switch to the CD16^{high}/CD62L^{low} subset in which this interaction was the most intense. Pertinently, 295 this PCNA-S100A8^{high} subset had increased ROS production, and increased CD11b and LOX1 expression as 296 compared to the conventional CD16^{high}/CD62L^{high} subset. Nonetheless, this PCNA-S100A8^{high} subset is not 297 immature since no decreased CD10 expression was observed compared to the main CD16^{high}/CD62L^{high} 298 subset. Further investigations are required to decipher the immunomodulatory functions of this PCNA-299 S100A8^{high} subset⁷⁰ which accounts for more than 10% of the circulating neutrophils in COVID-19 patients 300 and which may be considered as a pathogenic and pro-inflammatory subpopulation. Accordingly, 301 inhibiting the molecular interaction between PCNA and S100A8 would provide a unique opportunity to 302 target this pro-inflammatory subset of neutrophils without affecting the general neutrophil population, 303 thereby avoiding neutropenia to maintain an efficient anti-infectious defense.

In conclusion, we propose that the increased neutrophil cytosolic PCNA is involved in the profound immune dysregulation observed in patients with severe COVID-19. Decoding the entire scaffold would certainly provide new insights into the molecular and functional dysregulation of neutrophils in patients with COVID-19.

308 Materials and methods

309 Human blood samples

310 Individuals hospitalized due to COVID-19 from April 2020 to January 2022 were recruited in Paris, at the 311 Cochin Hospital from the Internal Medicine department (authorization #2019-3677), the Respiratory 312 medicine department (authorization #2020 #A02700-39) and from the Intensive Care Medicine 313 department (authorization #2018 #A01934-51) and at Bichat Hospital from the Intensive Care Medicine 314 department (authorization #2020-715). This study was approved by the Hospital Ethics Committee, according to the Declaration of Helsinki. Each patient gave written informed consent and was classified 315 316 into different clinical severity groups (Table 1) depending on a multifactorial score taking into account oxygen requirement.^{34–36} Blood from COVID-19 patients and from healthy donors (HD) obtained from the 317 Etablissement Francais du Sang was collected in EDTA-vacuum or in dry tubes for serum collection. 318 319 Neutrophils were isolated in LPS-free dextran sedimentation and Ficoll (Histopaque-1077[°], Sigma-Aldrich) 320 centrifugation, as previously described.²²

321

322 Quantification of circulating neutrophil-derived activation markers

Circulating neutrophil elastase (ThermoFisher Scientific), calprotectin (S100A8/A9) (Biotechne) and
 Neutrophil Extracellular Traps (NETs) were measured by ELISA as previously described³⁷.

325

326 Neutrophil phenotype assessment using spectral flow cytometry

327 Blood neutrophils from HD or COVID-19 patients were labelled with the following antibodies: CD66b, 328 CD15, CD62L, CD16, CD11b, CXCR2, PD-1, CD45, CD10, CD33, CD114, PDL-1, GLUT-1, LOX-1 or their 329 respective isotypes (Table 3). Samples were acquired in a Cytek Aurora cytometer (Cytek Biosciences, 330 Fremont, CA, USA). Data were analyzed using FlowJo v10.7.1 software (FlowJo LLC) (Supplemental Figure 331 1). Neutrophil phenotype was also evaluated by unsupervised analysis using the ti-SNE dimensional 332 reduction algorithm. A sample of 30000 neutrophils (CD15⁺ cells) from each individual were normalized 333 and pulled down. Then, cells were grouped and subjected to the algorithm to form homogeneous clusters 334 based on CD16, CD62L, CD10, CD11b, CD66b and LOX-1 surface expression using the CytoBank platform 335 (Beckman Coulter Life Sciences, California).

336

337 Assessment of physiological apoptosis

338 Neutrophils (2 x 10^6 cells/mL in RPMI-1640-10% FBS) were incubated overnight (16h, 37° C, 5% CO₂) and

then labeled with annexin-V (Miltenyi Biotec) and 7-AAD (BD Biosciences) as previously described.²² To

- assess mitochondrial integrity, neutrophils were stained with 1 µM of 3,3'-dihexyloxacarbocyanine iodide
 (DiOC6), a fluorescent dye selective for live cell mitochondria^{38,39} (ThermoFisher). Data acquisition was
 performed using BD-Accuri[™]-C6Plus, analyzed by Cflow Plus software.
- 343

344 Evaluation of NADPH-oxidase-dependent ROS production

345 Isolated neutrophils (0.1 x 10⁶ cells) were suspended in 0.1 mL HBSS with or without T2AA (Sigma-Aldrich) 346 at indicated concentrations for 1 h ($37^{\circ}C$, $5\% CO_{2}$). Neutrophils were then stimulated with or without PMA 347 (Sigma-Aldrich; 0.1 µg/ml), IgG- and complement proteins-opsonized zymosan (0.5 mg/mL), or N-Formyl-348 methionine-leucyl-phenylalanine (f-MLF) (Sigma-Aldrich; 10 µM) as previously described (Ohayon et al 349 2019). Chemiluminescence was recorded after addition of luminol (Sigma-Aldrich; 10 μM) at 37°C in a TRISTAR luminometer (Bertold, Wild bad Germany) over time. The data were expressed as integrated total 350 351 counts, processed by the microWim software and analyzed using Prism 9.3 software. In order to 352 characterize the membrane phenotype of ROS-producing neutrophils, cells were first loaded with 10 μM 353 of cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, Thermo Fisher) and were stimulated 354 with or without PMA or opsonized zymosan and were next stained with a mix of anti-human CD16 and 355 CD62L to determine neutrophil subpopulations. Samples were acquired in a Cytek Aurora (Cytek 356 Biosciences, Fremont, CA, USA) cytometer and approximately 100 000 gated events were used in each 357 analysis (Supplemental Figure 1). Data were analyzed using FlowJo v10.7.1 software (FlowJo LLC).

358

359 Western blot analysis of PCNA and S100A8

360 Neutrophil cytosol was obtained by sonication in a hypotonic HEPES buffer (50 mM) supplemented with 361 inhibitors (4 mM PMSF, 400 µM leupeptin, 400 µM pepstatin, 1 mM orthovanadate, 1 mM EGTA, and 1 362 mM EDTA) and DTT (1 mM), with a Soniprep 150 Plus sonicator (1 Hz for 10 s) as previously described.⁴⁰ 363 Alternatively, neutrophils were lysed in the sonication buffer supplemented with 1% NP40 detergent to 364 obtain a whole cell lysate. Protein concentration was measured using the BCA kit (Pierce). Samples diluted into Laemmli buffer (30 µg per well) were subjected to SDS-PAGE, transferred to polyvinylidene difluoride 365 366 (PVDF) membrane (PerkinElmer Life Sciences). After blocking with Tris-buffered saline (TBS) containing 367 5% nonfat dry milk, membranes were probed with mouse monoclonal anti-PCNA (PC10; 1:1000 dilution), goat polyclonal anti-S100A8 (Everest, EB11513; 1:1000 dilution), goat polyclonal anti-actin (Sigma A2066; 368 369 1:1000 dilution) antibodies overnight at 4°C. Secondary horseradish peroxidase-conjugated-linked anti-370 rabbit IgG (Jackson Lab, 111-035-003; 1:5000), anti-mouse IgG (Jackson Lab, 115-036-006; 1:2000) or anti-371 goat IgG (Santa Cruz biotechnology, sc-2033; 1:4000) antibodies were applied 1h at room temperature as

previously described (Witko-Sarsat et al 2010). Immunoreactivity was visualized using enhanced
 chemiluminescence reagents (Amersham Biosciences). Images were acquired and quantified using a
 Fusion FX7 system imaging (Vilbert Lourmat).

375

PCNA and S100A8 detection using indirect immunofluorescence or the Duolink[®] proximity ligation assay (PLA)

378 Cells were fixed in 2% formaldehyde/PBS for 20 min on ice and permeabilized with 0.25% Triton X-100 for 5 min at room temperature, followed by ice-cold methanol for 10 min, incubated with the rabbit 379 380 polyclonal anti-PCNA (Ab5; 1:25) or the mouse monoclonal anti-S100A8 (2H2; 1:100) antibodies for 45 381 min. PCNA incubation was followed by biotinylated anti-rabbit IgG (Dako; 1:200) for 30 min, and then by streptavidin-coupled Alexa Fluor 555 (Invitrogen; 1:1000) for 30 min. S100A8 incubation was followed by 382 383 anti-mouse IgG Alexa Fluor 488 (Invitrogen; 1:100) for 30 min. Nuclei were stained with DAPI containing mounting media (Sigma Aldrich) as previously described.²² Red fluorescence was observed with a 488-384 385 560 nm-long-pass emission filter under 543 nm laser illumination. Images were processed using ImageJ 386 software version 1.53J (National Institutes of Health) and fluorescence normalized to DAPI fluorescence 387 as previously described

For Duolink[®] PLA assay, neutrophils (0.3 x 10⁶) were processed as described by the manufacturer using a mix of anti-PCNA (Ab5; 1:100) and anti-S100A8 (2H2; 1:100) as primary antibodies either on cytospins or in suspension for microscopic or flow cytometry analysis, respectively. Detection was achieved if distance between the two targeted epitopes are up to 40 nm. Fluorescence was acquired under microscopy (Widefield Zeiss Observer Z1 and SR Leica SP8X STED Flim) or by FACS (Cytek Aurora) gating at least 100 000 neutrophils. Data were analyzed using ImageJ 1.53J and FlowJo v10.7.1 softwares, respectively.

394

395 Analysis of PCNA-S100A8 interaction by surface plasmon resonance (SPR)

396 PCNA was obtained using *E. coli* vector expression and purification as previously described³⁰. Interactions 397 between PCNA and recombinant human (rh) \$100 proteins (R&D systems, Biotechne, MN, USA) were 398 studied by SPR on a Biacore T200 (GE Healthcare) designed to calculate affinity and kinetic parameters as 399 previously described.^{22,31} Briefly PCNA was covalently immobilized on a dextran layer sensor chip (CM5) 400 while the rh S100A8 (9876-S8), S100A9 (9254-S9) or S100A8/A9 (8226-S8) (1:1 complex) protein at the 401 indicated concentrations (0.1–2 μ M) were used as analytes in a running buffer as previously described. In 402 all experiments, the specific binding signal was obtained by subtracting the background signal. For global 403 fitting we used kinetic titration on the Biacore T200 system, referred to as multiple-cycle kinetics, to

collect binding data for kinetic analysis. This method involves sequential injections of several analyte
 concentrations over the ligand immobilized on the sensor chip surface after a regeneration step between
 successive injections by 5 mM EDTA. The association (K_a) and dissociation (K_d) rate constants and K_D were
 calculated using BIAevaluation software. The simplest 1:1 Langmuir binding model was first tested. The
 heterogeneous ligand model was used as it significantly increased the statistical goodness-of-fit based on
 the *Chi²* value as calculated by Biacore software. This model accounts for the presence of two sites that
 bind analyte independently of each other.

411

412 Statistical analysis

- 413 Data are expressed as mean ± standard error of the mean (SEM) from (n) independent experiments
- 414 performed on neutrophils isolated from different donors or patients and analyzed by one-way ANOVA
- followed by Dunnett's or Tukey's test. For paired comparisons, Student's t-test was used. GraphPad
- 416 Prism Software 9.0 was used for data processing (**P* < 0.05; ***P* < 0.01; ****P* < 0.001 were considered
- 417 statistically significant).

418 Online supplemental material

- 419 Supplemental Figure 1. Representative gate strategy used for neutrophils analysis by flow cytometry.
- 420 Supplemental Figure 2. Re-analysis of publicly available RNA-seq data of PCNA and S100A8. Expression of
- 421 PCNA and S100A8/A9 genes in circulating and respiratory tract-infiltrated neutrophils from COVID-19422 patients.
- 423 Supplemental Figure 3. Concentration-response curve of T2AA, a PCNA inhibitor, in the activation of
- 424 NADPH-oxidase in neutrophils from healthy controls and critical COVID-19 patients.
- 425 Supplemental Figure 4. Phenotypic characterization of whole blood neutrophils in COVID-19 patients.
- 426 Supplemental Figure 5. Phenotypic characterization of low-density-neutrophils in the PBMCin COVID-19
- 427 patients.

428 Author contributions

All named authors meet the general criteria for authorship of this manuscript and have given final
approval for publication. ROF, LP, LT, SM, VK, KB, MA and VWS designed experiments and analyzed data;
ROF, LP, VK, SM, ML, LT, TD, MS, ELR, EPL, PF, VG, LCM, FS, CR, MC performed experiments; MHN, AH,
SCM, PRB, LM, CM, FP contributed with critical reagents/tools/clinical samples; ROF, LP, ML, LT and VWS
wrote the manuscript.

434 435

436 Acknowledgments

We are grateful for the excellent technical help provided by Giovanni Saracenti-Tasso to isolate
neutrophils and to measure the respiratory burst, Thomas Guilbert (IMAGIC/Institut Cochin) and Nicolas
Cagnard (Bioinformatics Core Platform/Imagine Institute) for the technical support. We thank Molly
Ingersoll and Karen Aymonnier for review and feedback on the manuscript.

This study was supported by the Fondation pour la Recherche Médicale Grant EQU202003010155 (VWS)
and the Investissements d'Avenir programme ANR-11-IDEX-0005-02, Sorbonne Paris Cite, LabEx
INFLAMEX (VWS); the French National Research Agency (ANR) with the Grant RA-COVID-19 V5COVINNATE (MHN); Grant DENDRISEPSIS ANR-17-CE15-0003 (FP); Grant APCOD ANR-17-CE15-0003-01
(FP); the Sao Paulo research Foundation Grant FAPESP-SCRIPPS 15/50387-4 (FS)

447

448 Disclosure of Conflicts of Interest

449 The authors declare no conflict of interest.

451 **REFERENCES**

- 1. Nauseef WM, Borregaard N. Neutrophils at work. *Nat Immunol*. 2014;15(7):602–611.
- Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. *Blood*.
 2019;133(20):2178–2185.
- 455 3. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic 456 inflammation. *Nat Rev Immunol*. 2017;17(4):248–261.
- 4. Dinauer MC. Inflammatory consequences of inherited disorders affecting neutrophil function. *Blood*.
 2019;133(20):2130–2139.
- 459 5. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in Health and Disease.
 460 *Trends Immunol.* 2019;40(7):565–583.
- 461 6. Allen L-AH, Criss AK. Cell intrinsic functions of neutrophils and their manipulation by pathogens. *Curr* 462 *Opin Immunol*. 2019;60:124–129.
- 463 7. Hidalgo A, Chilvers ER, Summers C, Koenderman L. The Neutrophil Life Cycle. *Trends Immunol*.
 464 2019;40(7):584–597.
- 465 8. Kobayashi SD, Malachowa N, DeLeo FR. Neutrophils and Bacterial Immune Evasion. *J Innate Immun*.
 466 2018;10(5–6):432–441.
- 467 9. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV468 2 infections. *Nat Med*. 2020;26(8):1200–1204.
- 469 10. Ribes A, Vardon-Bounes F, Mémier V, et al. Thromboembolic events and Covid-19. *Adv Biol Regul.*470 2020;77:100735.
- 471 11. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID472 19. *Nature*. 2020;584(7821):463–469.
- 473 12. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. *Am J Pathol.*474 2021;191(1):4–17.
- 475 13. Li S, Jiang L, Li X, et al. Clinical and pathological investigation of patients with severe COVID-19. *JCI*476 *Insight*. 2020;5(12):138070.
- 477 14. Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. *Sci Immunol*.
 478 2022;7(67):eabm5505.
- 479 15. Reyes L, A Sanchez-Garcia M, Morrison T, et al. A type I IFN, prothrombotic hyperinflammatory
 480 neutrophil signature is distinct for COVID-19 ARDS--. *Wellcome Open Res.* 2021;6:38.
- 481 16. Silvin A, Chapuis N, Dunsmore G, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets
 482 Discriminate Severe from Mild COVID-19. *Cell*. 2020;182(6):1401-1418.e18.
- 483 17. Guo Q, Zhao Y, Li J, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils
 484 in the pathogenesis of COVID-19. *Cell Host Microbe*. 2021;29(2):222-235.e4.
- 18. Pepper RJ, Hamour S, Chavele K-M, et al. Leukocyte and serum S100A8/S100A9 expression reflects
 disease activity in ANCA-associated vasculitis and glomerulonephritis. *Kidney Int*. 2013;83(6):1150–
 1158.
- 488 19. Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in
 489 rheumatoid arthritis and axial spondyloarthritis. *Arthritis Res Ther*. 2020;22(1):105.
- Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application.
 Pharmacol Ther. 2016;167:120–131.
- 492 21. Schenten V, Plançon S, Jung N, et al. Secretion of the Phosphorylated Form of S100A9 from
 493 Neutrophils Is Essential for the Proinflammatory Functions of Extracellular S100A8/A9. Front
 494 *Immunol.* 2018;9:447.
- Witko-Sarsat V, Mocek J, Bouayad D, et al. Proliferating cell nuclear antigen acts as a cytoplasmic
 platform controlling human neutrophil survival. *J Exp Med*. 2010;207(12):2631–2645.

497 23. Witko-Sarsat V, Ohayon D. Proliferating cell nuclear antigen in neutrophil fate. *Immunol Rev.*498 2016;273(1):344–356.

- 499 24. Kelman Z. PCNA: structure, functions and interactions. *Oncogene*. 1997;14(6):629–640.
- 500 25. Moldovan G-L, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. *Cell*. 2007;129(4):665–
 679.
- 502 26. Bouayad D, Pederzoli-Ribeil M, Mocek J, et al. Nuclear-to-cytoplasmic relocalization of the
 503 proliferating cell nuclear antigen (PCNA) during differentiation involves a chromosome region
 504 maintenance 1 (CRM1)-dependent export and is a prerequisite for PCNA antiapoptotic activity in
 505 mature neutrophils. *J Biol Chem.* 2012;287(40):33812–33825.
- Witko-Sarsat V, Pederzoli-Ribeil M, Hirsch E, et al. Regulating neutrophil apoptosis: new players enter
 the game. *Trends Immunol*. 2011;32(3):117–124.
- 28. Punchihewa C, Inoue A, Hishiki A, et al. Identification of small molecule proliferating cell nuclear
 antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. *J Biol Chem.* 2012;287(17):14289–14300.
- 511 29. Inoue A, Kikuchi S, Hishiki A, et al. A small molecule inhibitor of monoubiquitinated Proliferating Cell
 512 Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand
 513 break, and sensitizes cancer cells to cisplatin. *J Biol Chem.* 2014;289(10):7109–7120.
- S14 30. Ohayon D, De Chiara A, Chapuis N, et al. Cytoplasmic proliferating cell nuclear antigen connects
 glycolysis and cell survival in acute myeloid leukemia. *Sci Rep*. 2016;6:35561.
- S1. Ohayon D, De Chiara A, Dang PM-C, et al. Cytosolic PCNA interacts with p47phox and controls NADPH
 oxidase NOX2 activation in neutrophils. *J Exp Med*. 2019;216(11):2669–2687.
- S18 32. Kerkhoff C, Nacken W, Benedyk M, et al. The arachidonic acid-binding protein S100A8/A9 promotes
 NADPH oxidase activation by interaction with p67phox and Rac-2. *FASEB J*. 2005;19(3):467–469.
- 33. Berthier S, Nguyen MVC, Baillet A, et al. Molecular interface of S100A8 with cytochrome b558 and
 NADPH oxidase activation. *PLoS One*. 2012;7(7):e40277.
- 522 34. Lee EE, Hwang W, Song K-H, et al. Predication of oxygen requirement in COVID-19 patients using
 523 dynamic change of inflammatory markers: CRP, hypertension, age, neutrophil and lymphocyte
 524 (CHANeL). *Sci Rep.* 2021;11(1):13026.
- 35. Mellado-Artigas R, Ferreyro BL, Angriman F, et al. High-flow nasal oxygen in patients with COVID-19 associated acute respiratory failure. *Crit Care*. 2021;25(1):58.
- 527 36. Hvarfner A, Al-Djaber A, Ekström H, et al. Oxygen provision to severely ill COVID-19 patients at the 528 peak of the 2020 pandemic in a Swedish district hospital. *PLoS One*. 2022;17(1):e0249984.
- 529 37. Peyneau M, Granger V, Wicky P-H, et al. Innate immune deficiencies are associated with severity and 530 poor prognosis in patients with COVID-19. *Sci Rep*. 2022;12(1):638.
- 38. Moriceau S, Kantari C, Mocek J, et al. Coronin-1 is associated with neutrophil survival and is cleaved
 during apoptosis: potential implication in neutrophils from cystic fibrosis patients. *J Immunol*.
 2009;182(11):7254–7263.
- Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond.
 Nat Rev Mol Cell Biol. 2010;11(9):621–632.
- 40. Everts-Graber J, Martin KR, Thieblemont N, et al. Proteomic analysis of neutrophils in ANCAassociated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1
 involved in apoptotic cell clearance. *Kidney Int*. 2019;96(2):397–408.
- 539 41. Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium–immune
 540 cell interactions identified by single-cell analysis. *Nat Biotechnol*. 2020;38(8):970–979.
- 541 42. Chen L, Long X, Xu Q, et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are
 542 correlated with inferior clinical outcomes in COVID-19 patients. *Cell Mol Immunol*. 2020;17(9):992–
 543 994.

- 43. Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic inflammation inhibits
 T cell responses through Mac-1. *J Clin Invest*. 2012;122(1):327–336.
- 44. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil
 extracellular traps. *J Exp Med*. 2020;217(6):e20200652.
- 548 45. Zhang Y, Wang Q, Mackay CR, Ng LG, Kwok I. Neutrophil subsets and their differential roles in viral 549 respiratory diseases. *J Leukoc Biol*. 2022;111(6):1159–1173.
- 46. Cavalcante-Silva LHA, Carvalho DCM, Lima É de A, et al. Neutrophils and COVID-19: The road so far.
 Int Immunopharmacol. 2021;90:107233.
- 47. Hazeldine J, Lord JM. Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets.
 Front Immunol. 2021;12:680134.
- 48. Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. *J Exp Med*. 2020;217(12):e20201129.
- 49. Nathan C. Neutrophils and COVID-19: Nots, NETs, and knots. *J Exp Med*. 2020;217(9):e20201439.
- 557 50. Wilk AJ, Lee MJ, Wei B, et al. Multi-omic profiling reveals widespread dysregulation of innate 558 immunity and hematopoiesis in COVID-19. *J Exp Med*. 2021;218(8):e20210582.
- 559 51. Koenig LM, Boehmer DFR, Metzger P, et al. Blocking inflammation on the way: Rationale for CXCR2
 antagonists for the treatment of COVID-19. *J Exp Med*. 2020;217(9):e20201342.
- 561 52. González-Magaña A, Blanco FJ. Human PCNA Structure, Function and Interactions. *Biomolecules*.
 562 2020;10(4):E570.
- 53. Wang S-C. PCNA: a silent housekeeper or a potential therapeutic target? *Trends Pharmacol Sci.*2014;35(4):178–186.
- 565 54. Sprenkeler EGG, Zandstra J, van Kleef ND, et al. S100A8/A9 Is a Marker for the Release of Neutrophil
 566 Extracellular Traps and Induces Neutrophil Activation. *Cells*. 2022;11(2):236.
- 55. Kim DH, Choi E, Lee J-S, et al. House Dust Mite Allergen Regulates Constitutive Apoptosis of Normal and Asthmatic Neutrophils via Toll-Like Receptor 4. *PLoS One*. 2015;10(5):e0125983.
- 569 56. Kim DH, Gu A, Lee J-S, et al. Suppressive effects of S100A8 and S100A9 on neutrophil apoptosis by 570 cytokine release of human bronchial epithelial cells in asthma. *Int J Med Sci*. 2020;17(4):498–509.
- 57. Gilljam KM, Feyzi E, Aas PA, et al. Identification of a novel, widespread, and functionally important 572 PCNA-binding motif. *J Cell Biol*. 2009;186(5):645–654.
- 573 58. Prestel A, Wichmann N, Martins JM, et al. The PCNA interaction motifs revisited: thinking outside the
 574 PIP-box. *Cell Mol Life Sci.* 2019;76(24):4923–4943.
- 59. Spijkerman R, Bongers SH, Bindels BJJ, et al. Flow cytometric evaluation of the neutrophil
 compartment in COVID-19 at hospital presentation: A normal response to an abnormal situation. J
 Leukoc Biol. 2021;109(1):99–114.
- 578 60. Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid
 579 Cell Compartment. *Cell*. 2020;182(6):1419-1440.e23.
- 580 61. Lourda M, Dzidic M, Hertwig L, et al. High-dimensional profiling reveals phenotypic heterogeneity and
 581 disease-specific alterations of granulocytes in COVID-19. *Proc Natl Acad Sci U S A*.
 582 2021;118(40):e2109123118.
- 583 62. Spijkerman R, Jorritsma NKN, Bongers SH, et al. An increase in CD62Ldim neutrophils precedes the 584 development of pulmonary embolisms in COVID-19 patients. *Scand J Immunol*. 2021;93(6):e13023.
- 585 63. Kwok I, Becht E, Xia Y, et al. Combinatorial Single-Cell Analyses of Granulocyte-Monocyte Progenitor
 586 Heterogeneity Reveals an Early Uni-potent Neutrophil Progenitor. *Immunity*. 2020;53(2):303-318.e5.
- 587 64. Combadière B, Adam L, Guillou N, et al. LOX-1-Expressing Immature Neutrophils Identify Critically-III
 588 COVID-19 Patients at Risk of Thrombotic Complications. *Front Immunol*. 2021;12:752612.
- 589 65. Mukund K, Nayak P, Ashokkumar C, et al. Immune Response in Severe and Non-Severe Coronavirus
 590 Disease 2019 (COVID-19) Infection: A Mechanistic Landscape. *Front Immunol*. 2021;12:738073.

- 66. deKay JT, Emery IF, Rud J, et al. DEspRhigh neutrophils are associated with critical illness in COVID-19.
 Sci Rep. 2021;11(1):22463.
- 593 67. Shi H, Zuo Y, Yalavarthi S, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID594 19. *J Leukoc Biol*. 2021;109(1):67–72.
- 595 68. Metzemaekers M, Cambier S, Blanter M, et al. Kinetics of peripheral blood neutrophils in severe 596 coronavirus disease 2019. *Clin Transl Immunology*. 2021;10(4):e1271.
- 69. Bongers SH, Chen N, van Grinsven E, et al. Kinetics of Neutrophil Subsets in Acute, Subacute, and
 Chronic Inflammation. *Front Immunol*. 2021;12:674079.
- 599 70. Marini O, Costa S, Bevilacqua D, et al. Mature CD10+ and immature CD10- neutrophils present in G-600 CSF-treated donors display opposite effects on T cells. *Blood*. 2017;129(10):1343–1356.
- 601

603 FIGURE LEGENDS

604 Figure 1. PCNA is overexpressed in the cytosol of neutrophils and is associated with COVID-19 605 severity. (A-B) Western blot analysis of PCNA expression in neutrophils cytosols from HD (n = 17), 606 moderate (n = 5), severe (n = 6), and critical (n = 12) COVID-19 patients. (A) Representative 607 experiment. (B) Quantification of Western blots. Data are expressed as fold change in reference 608 to PCNA expression in HD. (C-D) Neutrophils from HD (n = 5), severe or critical COVID-19 patients (n = 5) were labeled with a rabbit polyclonal anti-PCNA antibody and with DAPI to visualize nuclei 609 610 using the Widefield Zeiss Observer Z1 microscope (magnification x 100). (C) Representative 611 experiment of indirect immunofluorescent staining of PCNA showing its cytosolic localization 612 (red) and the nuclei (blue). (D) Quantification of the PCNA immunolabelling fluorescence. Photos 613 were captured from at least 3 different fields for a given donor and each point corresponds to 614 the mean of a different donor. (E-G) Soluble inflammation markers were measured: (E) NETs, as MPO-DNA complexes; (F) Elastase and (G) S100A8/A9 (calprotectin), by ELISA in serum from HD 615 616 (n = 12) moderate (n = 7) severe (n = 18) and critical (n = 17) COVID-19 patients. (H-J) Correlation 617 between normalized cytosolic PCNA expression measured by Western blot in neutrophils from 618 patients with all levels of COVID-19 severity (as in B) and the circulating concentration of (H) NETs 619 (I) Elastase and (J) Calprotectin. Pearson correlation coefficient are indicated and the associated probability is: **p = 0.007, *p = 0.014 and *p = 0.024, respectively. Graph symbols represent 620 individual donors. In B, D, E, F, and G data are presented as mean ± SEM. Data was analyzed by 621 one way-ANOVA followed by Tukey or Dunnett post-test or by Student's t-test when two 622 individual groups were compared (*p<0.05; **p<0.01; ***p<0.001). 623

624

Figure 2. Increased neutrophils survival in COVID-19 is reversed by the PCNA inhibitor T2AA.

(A-D) Spontaneous apoptosis was induced by overnight incubation of neutrophils from HD (n = 10) severe or critical COVID-19 patients (n = 10) at 37°C, 5% CO₂ for 16 h in the presence or absence of the PCNA inhibitor T2AA (5 μ M) (A) Percentage of viable neutrophils with annexin-V⁺/7-AAD⁺ labelling. (B) Percentage of apoptotic neutrophils with annexin-V⁺/7-AAD⁻ labelling. (C) Percentage of necrotic neutrophils with annexin-V⁺/7-AAD⁺ labelling. (D) Flow cytometry measurement of DIOC6 labelling to assess mitochondria integrity. MFI of DiOC6 staining is

632 indicative of intact mitochondrial membrane potential and is decreased upon apoptosis. (E) PCNA 633 expression measured by Western blot in cytosols from freshly isolated neutrophils at basal state 634 [B] or following a 16h-incubation triggering spontaneous apoptosis [A]. PCNA abundance was quantified by densitometry and normalized using Ponceau red staining. Data are the mean of 635 three independent experiments carried out with neutrophils from HD and COVID-19 patients 636 with different disease severity (moderate, severe, or critical). In A, B, C and D, graph symbols 637 represent individual donors. Data are presented as mean \pm SEM and were analyzed by one way-638 ANOVA followed by Tukey or Dunnett post-test or by Student's t-test when two individual groups 639 were compared (***p<0.001). 640

641

Figure 3. PCNA regulates NADPH oxidase-dependent ROS production in COVID-19. NADPH 642 oxidase activation was assessed by using luminol-enhanced chemiluminescence (CL) that 643 measured ROS production in isolated neutrophils from HD (n = 7), moderate (n = 8), severe (n = 8) 644 14) and critical (n = 17) COVID-19 patients under (A) basal or following stimulation by (B) PMA 645 $(0.1 \,\mu\text{g/mL})$, (C) opsonized zymosan (0.5 mg/mL) or (D) f-MLF (1 μ M). These measurements were 646 647 performed in the absence or in the presence of the PCNA inhibitor, T2AA (5 μ M). CL was recorded at 37°C in a Tristar[™] luminometer over time and data were expressed as arbitrary units (AU) at 648 the peak of ROS production. (E-F) Assessment of the PCNA-p47^{phox} interaction in neutrophils. The 649 Duolink[®] proximity ligation assay (PLA) was performed on isolated neutrophils from HD (n=5) or 650 651 severe or critical COVID-19 patients (n=5). Neutrophils were incubated in the absence or in the 652 presence of PMA for 10 min to trigger NADPH oxidase activation. (E) Representative experiment 653 of PLA staining using rabbit polyclonal anti-PCNA antibody associated with mouse monoclonal anti- p47^{phox} antibody showing the interaction of PCNA and p47^{phox} (red) and the nuclei labelled 654 by DAPI (blue) and visualized using the Widefield Zeiss Observer Z1 microscope (magnification x 655 100). (F) Quantification of the PCNA-p47^{phox} proximity-induced fluorescence. Photos were 656 captured from at least 3 different fields for a given donor and MFI was analyzed, each point 657 658 corresponds to the mean of a different donors. Graph symbols represent individual donors. Data 659 are presented as mean ± SEM. Data was analyzed by one way-ANOVA followed by Tukey or

Dunnett post-test or by Student's t-test when two individual groups were compared (*p<0.05;
 ***p<0.001).

662

Figure 4. S100A8 is a partner of PCNA overexpressed in neutrophils cytosols from COVID-19 663 patients. (A) Data represent overlays of sensorgrams resulting from injection of human 664 665 recombinant S100A8 at different concentrations $(0.1 - 2 \mu M)$. Fits with a statistic χ^2 value 7.6 are shown as dotted lines (RU: response units). SPR experiments were performed on a Biacore T200 666 apparatus. Kinetic values determination is reported in Table 2. Interaction was predicted under 667 a standard curve composed of baseline, association, equilibrium, and dissociation phases. (B) SPR 668 669 measurements of human recombinant S100A8, S100A9 or S100A8/A9 (2 µM) binding on immobilized PCNA. (C) Representative experiment of the assessment of the PCNA-S100A8 670 interaction in isolated neutrophils using the Duolink[®] proximity ligation assay (PLA). PCNA-671 S100A8 proximity-induced fluorescence was detected (red) using a rabbit polyclonal anti-PCNA 672 and a mouse monoclonal anti-S100A8. Prior to experiment, neutrophils were incubated in the 673 674 absence or presence of T2AA (5 μM) for 30 min. DAPI was used for nuclear staining (blue) Cells were visualized using the SR Leica SP8X STED Flim confocal microscope (magnification x100) (D) 675 Quantification of the PCNA-S100A8 proximity-induced fluorescence. Photos were captured from 676 677 at least 3 different fields for a given donor and MFI was analyzed, each point corresponds to the 678 mean of a different donors (E) Western blot analysis of S100A8 expression in neutrophils cytosols from HD (n = 17), moderate (n = 5), severe (n = 6), and critical (n = 6) COVID-19 patients. (F) 679 Quantification of S100A8 abundance by densitometry. Western blot analysis of actin was 680 performed on the same membranes and used as a loading control for the normalization of PCNA 681 expression. (G) Correlation between normalized PCNA and S100A8 expressions measured by 682 Western blot in neutrophils from patients with all levels of COVID-19 severity. Pearson 683 correlation coefficient are indicated and the associated probability is **p = 0.004. (H-I) 684 685 Neutrophils from HD (n = 5), severe or critical COVID-19 patients (n = 5) were labeled with a 686 mouse monoclonal anti-S100A8 antibody and with DAPI to visualize nuclei using the Widefield 687 Zeiss Observer Z1 microscope (magnification x 100). (H) Representative experiment of S100A8 immunofluorescent staining showing its cytosolic localization (red) and the nuclei (blue). (I) 688

Quantification of the S100A8 immunofluorescent staining. Photos were captured from at least 3 different fields for a given donor and MFI was analyzed in each field. Graph symbols represent individual donors. Data were analyzed by one way-ANOVA followed by Tukey or Dunnett posttest or by Student's t-test for two groups and shown as mean ± SEM (**p<0.01; ***p<0.001).

693

Figure 5. Neutrophils in COVID-19 patients present an altered phenotype linked to activation 694 and immaturity. (A) Whole blood from HD (n = 7), severe (n = 10) and critical (n = 10) COVID-19 695 patients were used for leukocytes staining and the assessment of 13 surface markers was 696 performed by spectral flow cytometry on a Cytek Aurora cytometer. Analysis was conducted in 697 698 CD15⁺ cells using the gate strategies shown in Supplemental Figure 1. Results are expressed by MFI for each marker. (B) t-Distributed Stochastic Neighbor Embedding (t-SNE) plots showing 699 neutrophil heterogeneity. Analysis was performed in $CD15^+$ cells (n = 30000 down sampled) 700 comparing HD (n = 5), severe (n = 5) and critical (n = 5) COVID-19 patients. Data were analyzed 701 by one way-ANOVA followed by Tukey or Dunnett post-test or by Student's t-test for two groups 702 and shown as mean ± SEM (**p<0.01; ***p<0.001). 703

704

705 Figure 6. PCNA-S100A8 interaction is increased in an hyperactivated subset of neutrophils in **COVID-19.** (A) Representative flow cytometry dot plot showing the distinct neutrophil subsets 706 707 according to CD16 and CD62L membrane labelling in neutrophils (CD15⁺ cells). Different subsets are observed in the HD compared to the COVID-19 patient. The percentages of positive cells (%) 708 in the different CD16/CD62L neutrophil subsets that display CD16^{high}/CD62L^{high} (subset 1), 709 CD16^{high}/CD62L^{low} (subset 2), CD16^{low}/CD62L^{low} (subset 3) and CD16^{low}/CD62L^{high} (subset 4) 710 surface staining are presented. (B) Percentage of neutrophils in each CD16/CD62L subset. 711 712 Neutrophil phenotyping was performed in blood from HD (n = 7), severe (n = 10) and critical 713 (n=18) COVID-19 patients according to the gate strategy described in Supplemental Figure 1. (C) Flow cytometry quantification of the PCNA-S100A8 interaction by proximity-induced 714 fluorescence using Duolink[®] in the different neutrophil subsets (1-4) according to CD16/CD62L 715 surface expression. (D) Measurement of ROS production using dichlorofluorescin diacetate 716 (DCFDA) labelling in the different neutrophil subsets (1-4) according to CD16/CD62L surface 717

- 718 expression. DCFDA-loaded neutrophils were next fixed and labeled for CD16 and CD62L surface
- r19 expression. The expression of the surface markers (E) CD11b, (F) LOX-1 and (G) CD10 were also
- assessed in CD16/CD62L subset of neutrophils enriched in severe and critical COVID-19. Samples
- 721 were acquired in a Cytek Aurora. Graph symbols represent individual donors. Data were analyzed
- by one way-ANOVA followed by Tukey or Dunnett post-test or by Student's t-test for two groups
- 723 and shown as mean ± SEM (**p<0.01; ***p<0.001).

TABLES

Table 1. Clinical and biological characteristics of patients

	COVID-19			
	Moderate Severe (n=15) (n = 21)		Critical (n19)	
Male sex (n/%)	8 / 53.3%	14 / 66.7%	16 / 84.2%	
Female sex (n/%)	7 / 46.7%	7 / 33.3%	3 / 15.8%	
Age* (years)	76.9 ± 3.3 (42- 89)	68.7 ± 11.3 (44-92)	64.6 ± 2,4 (48- 77)	
Leukocytes** (/µl)	5910.7± 650	7367.5±2180.5	9326.5±1110	
Neutrophils** (/µL)	4206.43±665.2	5971.4±2150.3	8135.26±1123. 5	
CRP** (mg/dL)	NA	46.3±13	90.3±18.7	
D-Dimer** (ng/ml)	1212±253	1444±910	3293±1295	
Oxygenotherapy at inclusion (n)	6	21	17	
Oxygen flow < 3L/mn (n)	5	2	2	
Oxygen flow > 3L/mn (n)	1	10	10	
Nasal high flow oxygen (n, (%))	0	9 (42.9%)	5 (29.4%)	
Need for nasal high flow oxygen during hospitalization (n, (%))	4	15 (71.4%)	13 (68.4%)	
Systemic corticotherapy (n)	6	20	17	
Complete hospitalization duration (Days, Median (IQR))	16±2.5		15.7±3	
Death (n)	0	1	7	

*Results are expressed as mean ± SEM (min-max); **Results are expressed as mean ± SEM. NA: not available.

Moderate patients either do not require oxygen or require a flow of less than 3 L/min. Severe patients require COVID-19 oxygen flow between or over 3 L/min. Critically ill patients require more than 60% high flow oxygen and ventilation and have been recruited in the Intensive Care Unit (ICU).

	PCNA/S100A8					
Immobilized ligand/Soluble	K _{a1}	K _{d1}	K _{a2}	K _{d2} (s ⁻¹)	<i>K</i> _D (M)	Chi ²
analyte	(M ⁻¹ s ⁻¹)	(s ⁻¹)	(M ⁻¹ s ⁻¹)			
Heterogenous ligand model	2199	0.1035	138.1	0.0034	4.7 x 10 ⁻⁵ (K _{D1})	7.6
U					2.49 x 10 ⁻⁵ (K _{D2})	
1:1 model	158.5	0.00568	NA	NA	3.58 x 10⁻⁵	16.6

Table 2. Kinetics and affinity of PCNA interaction with S100A8

Binding of S100A8 (0.1-2 μ M) was measured as described in Materials and Methods section. Values were calculated for 1:1 and heterogeneous ligand models. The heterogeneous ligand model accounts for two different binding sites on the immobilized PCNA, and the two corresponding dissociation constants (K_{D1} and K_{D2}) were determined. NA = not applicable.

Surface marker	clone	Commercial source
CD66b	G10F5	BioLegend
CD15	W6D3	BD Biosciences
CD62L	DREG-56	BioLegend
CD16	3G8	BioLegend
CD11b	ICRF44	BioLegend
CXCR2	5E8	BioLegend
PD-1	EH12.1	BD Biosciences
CD45	2D1	BioLegend
CD10	HI10a	BD Biosciences
CD33	P67.6	BD Biosciences
CD114	LMM741	BD Biosciences
PDL-1	MH3	BioLegend
GLUT-1	1418G	R&D Systems
LOX-1	15C4	BioLegend

Table 3. Antibodies used for the phenotyping of neutrophils by flow cytometry.





Figure 2. Formiga et al.



PCNA-p47^{phox}







0

2

COVID-19

3 4

1

•

0-

1 2 3 4

•

COVID-19

Figure 6. Formiga et al.

0-

2 3 4

COVID-19